IPP Bureau
Shilpa Medicare & mAbTree Biologics win FDA nod for rare blood cancer therapy
By IPP Bureau - January 30, 2026
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
Mabtech & Sai Life Sciences launch strategic collab to revolutionize immunology research
By IPP Bureau - January 30, 2026
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
Thyrocare posts strong Q3FY26 results: revenue up 18%, PAT soars 47%
By IPP Bureau - January 30, 2026
Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%
By IPP Bureau - January 30, 2026
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
Vetter to invest €480 million in major German manufacturing expansion, eyes 2,000 jobs
By IPP Bureau - January 30, 2026
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
Moderna teams up with Recordati to commercialize rare disease therapy
By IPP Bureau - January 30, 2026
AstraZeneca pledges $15 billion investment in China through 2030
By IPP Bureau - January 30, 2026
UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."
BioMed X launches groundbreaking AI-driven diabetes research in Barbados
By IPP Bureau - January 30, 2026
With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease
Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience
By IPP Bureau - January 30, 2026
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Lonza posts CHF 6.5 billion in 2025 sales, marks strong profit growth
By IPP Bureau - January 30, 2026
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Fides launches imaging CRO focused on early-phase clinical decision-making
By IPP Bureau - January 30, 2026
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
INDIA-EU FTA unlocks access to $572.3 billion EU pharmaceuticals & medical devices market
By IPP Bureau - January 29, 2026
Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents
Lubrizol showcases India manufacturing expansion at WHX Dubai
By IPP Bureau - January 29, 2026
The Chennai facility will manufacture high-quality medical tubing for neurovascular and cardiovascular applications, including balloon catheters and other minimally invasive devices
Will Forte joins Teva Pharmaceuticals to shine spotlight on Huntington’s disease
By IPP Bureau - January 29, 2026
HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life
Roche’s investigational obesity drug CT-388 delivers dramatic weight loss in Phase II trial
By IPP Bureau - January 29, 2026
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
